High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core-binding factor

Takahiro Aoki; Norio Shiba; Shinichi Tsujimoto; Genki Yamato; Yusuke Hara; Shota Kato; Kenichi Yoshida; Seishi Ogawa; Yasuhide Hayashi; Shotaro Iwamoto; Tomohiko Taki; Akira Shimada; Yuka Iijima-Yamashita; Keizo Horibe; Akio Tawa; Takashi Taga; Souichi Adachi; Daisuke Tomizawa

doi:10.1002/pbc.30803

High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core-binding factor

Pediatr Blood Cancer. 2024 Feb;71(2):e30803. doi: 10.1002/pbc.30803. Epub 2023 Dec 6.

Authors

Takahiro Aoki¹, Norio Shiba², Shinichi Tsujimoto², Genki Yamato³, Yusuke Hara³, Shota Kato⁴, Kenichi Yoshida⁵, Seishi Ogawa^{6

7

8}, Yasuhide Hayashi⁹, Shotaro Iwamoto¹⁰, Tomohiko Taki¹¹, Akira Shimada¹², Yuka Iijima-Yamashita¹³, Keizo Horibe¹³, Akio Tawa¹⁴, Takashi Taga¹⁵, Souichi Adachi¹⁶, Daisuke Tomizawa¹⁷

Affiliations

¹ Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
² Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
³ Department of Pediatrics, Gunma University Graduate School of Medicine, Maebashi, Japan.
⁴ Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
⁵ Division of Cancer Evolution, National Cancer Center Research Institute, Tokyo, Japan.
⁶ Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁷ Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.
⁸ Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.
⁹ Institute of Physiology and Medicine, Jobu University, Takasaki, Japan.
¹⁰ Department of Pediatrics, Mie University, Tsu, Japan.
¹¹ Department of Medical Technology, Kyorin University Faculty of Health Sciences, Mitaka, Japan.
¹² Department of Pediatrics, Jichi Medical University, Shimotsuke, Japan.
¹³ Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
¹⁴ Higashiosaka Aramoto Heiwa Clinic, Higashiosaka, Japan.
¹⁵ Department of Pediatrics, Shiga University of Medical Science, Shiga, Japan.
¹⁶ Department of Human Health Science, Kyoto University, Kyoto, Japan.
¹⁷ Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.

PMID: 38054691
DOI: 10.1002/pbc.30803

Abstract

CD25 is an aberrant marker expressed on the leukemic stem cell (LSC) surface and an immunotherapy target in acute myeloid leukemia (AML). However, the clinical prevalence and significance of CD25 expression in pediatric AML are unknown. High IL2RA/CD25 expression in pediatric AML showed a stem cell-like phenotype, and elevated CD25 expression was associated with lower overall survival (p < .001) and event-free survival (p < .001) in the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study. This finding was reproduced in AML without a core-binding factor in the Children's Oncology Group study cohort. High CD25 expression has prognostic significance in pediatric AML.

Keywords: CD25; RNA sequencing; acute myeloid leukemia; children; leukemic stem cells.

MeSH terms

Biomarkers / metabolism
Child
Core Binding Factors*
Humans
Interleukin-2 Receptor alpha Subunit
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / therapy
Neoplastic Stem Cells
Prognosis

Substances

Core Binding Factors
Biomarkers
IL2RA protein, human
Interleukin-2 Receptor alpha Subunit